GSK plc (GSK,GSK.L) announced that its B7-H3-targeted antibody-drug conjugate GSK'227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan Drug Designation from the FDA for the treatment of small-cell lung cancer. The ODD was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC who were treated with risvutatug rezetecan in the phase I ARTEMIS-001 clinical trial.
The company said the designation follows the recent announcement that risvutatug rezetecan was granted ODD from the European Medicines Agency for the treatment of pulmonary neuroendocrine carcinoma, a category of cancer that includes SCLC.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.